IP Library › Granted Patent US 10,385,360
Granted Patent B2
US 10,385,360 · App. 15/925,544 · Granted Aug 20, 2019

Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

Inventors: Jennifer A. Doudna (Berkeley, CA); Martin Jinek (Berkeley, CA); Krzysztof Chylinski (Vienna, AT); Emmanuelle Charpentier (Braunschweig, DE)
Assignees: The Regents of the University of California; University of Vienna; Emmanuelle Charpentier
C12N15/907A01H6/4684A01K67/027A61K38/465C12N9/22C12N15/102C12N15/111C12N15/113C12N15/63C12N15/70C12N15/746C12N15/90C12N15/902A61K48/00C12N2310/11C12N2310/13C12N2310/14C12N2310/20C12N2310/31C12N2310/32C12N2310/33C12N2310/3519C12N2310/531C12N2800/80C12Y301/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,360
App. No.
15/925,544
Filed
Mar 19, 2018
Granted
Aug 20, 2019
Kind
B2
Art Unit
1636
USPC
424/94.3
Abstract

The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.

Claims (16)

1. A nucleic acid molecule encoding a single molecule DNA-targeting RNA, wherein the single molecule DNA-targeting RNA comprises:

(a) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a target sequence in a target DNA molecule, and

(b) a protein-binding segment comprising two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein said two complementary stretches of nucleotides are covalently linked to one another with intervening nucleotides,

wherein the DNA-targeting segment is positioned 5 ′ of both of said two complementary stretches of nucleotides, and wherein the single molecule DNA-targeting RNA is capable of forming a complex with a Cas9 protein and targeting the complex to the target sequence of the target DNA molecule.

2. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is a recombinant expression vector.

3. The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule is a vector selected from the group consisting of plasmids, cosmids, minicircles, phage, and viral vectors.

4. A composition comprising:

(1) a single molecule DNA-targeting RNA, or a nucleic acid encoding said single molecule DNA-targeting RNA, wherein the single molecule DNA-targeting RNA comprises:

(a) a DNA-targeting segment comprising a nucleotide sequence that is complementary to a target sequence in a target DNA molecule, and

(b) a protein-binding segment comprising two complementary stretches of nucleotides that hybridize to form a double stranded RNA (dsRNA) duplex, wherein said two complementary stretches of nucleotides are covalently linked to one another with intervening nucleotides,

wherein the DNA-targeting segment is positioned 5 ′ of both of said two complementary stretches of nucleotides, and wherein the single molecule DNA-targeting RNA is capable of forming a complex with a Cas9 protein and targeting the complex to the target sequence of the target DNA molecule; and

(2) one or more of: (i) a nuclease inhibitor, (ii) a buffering agent, and (iii) a pharmaceutically-acceptable, non-toxic carrier or diluent.

5. The composition of claim 4 , comprising the buffering agent.

6. The composition of claim 5 , wherein the buffering agent is a buffer for stabilizing nucleic acids.

7. The composition of claim 4 , further comprising one or more of: a detergent, a carbohydrate, a polyamine, an amino acid, a peptide, sodium, potassium, calcium, magnesium, manganese, and a lipid.

8. The composition of claim 4 , wherein the composition is sterile.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2018
From: DOUDNA, JENNIFER A.; JINEK, MARTIN; QI, LEI S.; DOUDNA CATE, JAMES HARRISON; LIM, WENDELL A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 045306/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2018
From: CHYLINSKI, KRZYSZTOF
To: UNIVERSITY OF VIENNA
Reel/Frame 045306/0869 →
Continuity (19)
Continuation 15435233 · Feb 16, 2017
Continuation 15138604 · Apr 26, 2016
Continuation 14942782 · Nov 16, 2015
Continuation 13842859 · Mar 15, 2013
Continuation 14685516 · Apr 13, 2015
Continuation 13842859 · Mar 15, 2013
Continuation 14685514 · Apr 13, 2015
Continuation 13842859 · Mar 15, 2013
Continuation 14685513 · Apr 13, 2015
Continuation 13842859 · Mar 15, 2013
Continuation 14685504 · Apr 13, 2015
Continuation 13842859 · Mar 15, 2013
Continuation 14685502 · Apr 13, 2015
Continuation 13842859 · Mar 15, 2013
Provisional Application 61765576 · Feb 15, 2013
Provisional Application 61757640 · Jan 28, 2013
Provisional Application 61716256 · Oct 19, 2012
Provisional Application 61652086 · May 25, 2012
Related Publication 20180208931A1 · Jul 26, 2018
Cited By (4)
US 12,201,699 US 12,286,727 US 12,297,466 US 12,338,436